Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
Equillium’s add-on lupus treatment improved a biomarker of kidney function in an unblinded phase 1 study, setting the ball rolling toward Ono Pharmaceuticals’ court for future development work.
Biotechnology major Biocon on Wednesday said it has initiated a clinical study in collaboration with Equillium Inc to evaluate efficacy of Itolizumab in patients with Ulcerative Colitis.
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the second quarter 2022 and provided an update on its clinical development programs.
LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced the initiation of the EQUATOR study, a pivotal Phase 3 clinical study of itolizumab in patients with acute graft-versus-host disease (aGVHD). The randomized, double-blind study will assess the efficacy and safety of itolizumab versus placebo as a first-line therapy for aGVHD in combination with corticosteroids. The primary objective of the study is to achieve early disease response, with key secondary objectives to evaluate durability of response, corticosteroid use, survival outcomes, and chronic GVHD incidence. The primary endpoint assessment is complete response (CR) rate at Day 29, with key secondary endpoints of overall response rate (ORR) at Day 29 and durability of CR rate from Day 29 through Day 99.
LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will participate in a fireside chat presentation at the SVB Leerink Virtual Global Healthcare Conference, taking place February 14 – 18, 2022.
LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that the Phase 1b EQUIP study of itolizumab in patients with uncontrolled asthma met its primary objective of safety and tolerability and demonstrated on-target peak and sustained reduction of CD6 at Day 85 (one month following last dose). Itolizumab is a first-in-class anti-CD6 monoclonal antibody that targets the CD6-ALCAM signaling pathway to selectively inhibit pathogenic T effector cells.
Biocon Biologics yesterday announced that the US-based Equillium Inc, Biocon’s partner, has expanded its Equalise study in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis for Itolizumab (ALZUMAb-L) to clinical centres in India. Equalise is a phase-Ib open-label, proof-of-concept clinical study currently studying Lupus Nephritis patients in the Part B portion of the clinical trial, the company notified via a statement.
Biocon Biologics, an arm of biotechnology major Biocon, on Thursday said the clinical study for its biologic drug Itolizumab for the possible indication in autoimmune disease Lupus Nephritis has been initiated in India after approval from the Drugs Controller General of India. Biocon's partner US-based Equillium Inc has expanded its 'EQUALISE' study in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis for Itolizumab to clinical centers in India, Biocon Ltd said in a regulatory filing.